PER-058-01已完成未知
REVISED CLINICAL PROTOCOL FOR A RANDOMIZED, DOUBLE-BLIND, CONTROLLED BY PLACEBO, STUDY TO COMPARE THE ANALGESIC ACTIVITY OF VALDECOXIB (SC-65872) 40 MG TWICE PER DAY AS ADDITIVE MEDICATION THERAPY OPIATES IN PATIENTS WITH CHRONIC CANCER PAI
PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,0 个研究点目标入组 0 人开始时间: 2001年8月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •The patient suffers from chronic pain related to cancer or as a result of previous cancer therapy, which is assumed to last at least 90 days. The main component of this pain should be visceral pain and / or nociceptive somatic base.
- •The patient required daily opioid analgesic medication (> 5 days per week) for at least two weeks prior to entering the study, and is expected to require daily opioid medication throughout the course of the study.
- •The patient met the criteria for pain intensity, total daily opioid use, and adverse events, established for the Stabilization Phase.
- •The patient must have the legal age to grant consent, or be older than that age.
- •Weight> 50 kg.
- •The female patient is postmenopausal, surgically sterile, or uses an adequate method of contraception, is not breastfeeding or nursing a baby, and presented a negative pregnancy test in serum within 14 days before starting the study.
- •The patient presents a Kamofsky Performance Score> 60 at the baseline
- •The patient has an expectation of life> 4 months from the beginning of the study.
- •The patient provided written informed consent before carrying out any procedure related to the study.
排除标准
- •Those patients whose pain is classified mainly as neuropathic or of unknown nature.
- •The patient received an agent under investigation within 30 days prior to the first dose of the study medication, or is scheduled to receive a drug under investigation other than valdecoxib during the course of the study.
- •Those patients who are currently participating in a research chemotherapy trial.
- •Those patients in whom the initiation of the use of a new chemotherapeutic agent is expected in less than three weeks before the first dose of the study medication until Day 42 of the same.
- •Patients who are using active oncology therapy within two weeks of receiving the first dose of the study drug (study entry) until Day 42 of the study, which is expected to confuse the evaluation of efficacy or safety analgesic
- •Those patients who are scheduled to undergo a therapeutic procedure (for example, surgery or biopsy), with the possibility of influencing their pain intensity until Day 42 of the study.
- •The reception of radiopharmaceutical treatment or radiotherapy within 4 weeks prior to receiving the first dose of the study drug, until Day 42 thereof.
- •History of cancer of the esophagus or gastric.
- •Patients with AIDS or with cancers related to AIDS.
- •Known significant hepatic insufficiency (Ciase B or C of Child-Pugh).
- •Those patients who have been diagnosed or have received treatment for esophageal, gastric, pyloric or duodenal channel ulceration, within 30 days prior to receiving the first dose of the study medication.
- •Known renal insufficiency, creatinine level> 1.5 mg / dl, blood urea nitrogen [BUN]> 1.5, the upper limit of normal, or a creatinine clearance, if known, <50 ml / minute.
- •Platelet count <40,000, or impaired platelet function.
- •Presence or history of a disease or unstable condition that, in the opinion of the investigator, would exclude the participation of the patient in the trial.
- •Inability to take tablets or tolerate oral medication.
- •Intractable nausea and vomiting.
- •History of hypersensitivity to cyclooxygenase inhibitors (DAINEs, specific inhibitors of COX-2) or opioids.
- •The patient will begin the use of bisphosphonates within 8 weeks of entering the study, until Day 42 of the same. Patients who have started bisphosphonate therapy 8 weeks before the first dose of the study drug can continue using bisphosphonates as indicated.
- •Concomitant use of antidepressants, antiepileptic drugs, corticosteroids or antihistamines used as analgesic aids, unless such therapy has been initiated in a period greater than 2 weeks before the first dose of the study drug.
- •Scheduled use of any analgesic, specific inhibitors of COX-2, or DAINEs different to that established by the protocol during the study period. (The use of acetaminophen <2 grams / day for 2 days or less per week is allowed).
- •Physical / mental inability to answer questions and comply with the treatment protocol.
- •History of significant abuse of alcohol, analgesics, or narcotic substances within six months prior to the Selection.
- •The patient was admitted prior to the study.
研究者
相似试验
已完成
不适用
CLINICAL PROTOCOL OF A RANDOMIZED, DOUBLE-BLIND STUDY, PLACEBO CONTROLLED IN PARALLEL GROUPS, TO COMPARE THE VALDECOXIB ANALGESIC ACTIVITY (SC-65872) 40 MG, TWICE A DAY IN PATIENTS WITH CHRONIC PAIN BY CANCERPER-068-01PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
已完成
不适用
CLINICAL PROTOCOL FOR A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF A SINGLE DOSAGE OF PARODOXIB SODIUM IV VS. A SINGLE DOSE OF KETOPROPHENE IV VS. ONE UNIQUE DOSAGE OF KETOROLACO IV VS. PLACEBO FOR THE TREATMENT OF PAIN AFTER A LAPAROSCOPIC COLLECISECTOMY.PER-077-02PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
已完成
3 期
CONTROLLED, DOUBLE-BLIND, RANDOMIZED, MULTICENTER, FASE IIIb TRIAL DESIGNED TO EVALUATE THE EFFICACY AND TOLERABILITY OF THE FIXED COMBINATION OF THIOCOLCHICOSIDE PLUS DICLOFENAC POTASSIUM IN ACUTE PAINFUL MUSCLE CONTRACTUREAcute painful striated muscle contracture,(cervical pain, backache, low back pain without sciatica, etc.)RPCEC00000162Gutis Ltda. San Jose, Costa Rica90
已完成
不适用
Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)-C18 Malignant neoplasm of colonMalignant neoplasm of colonC18PER-069-01PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,
进行中（未招募）
1 期
A clinical trial for a guided early administration of antibiotics for presumed infection at the EREUCTR2018-001008-13-GRHELLENIC INSTITUTE FOR THE STUDY OF SEPSIS220